An experimental immunotherapy developed by Bristol Myers Squibb prevented metastatic melanoma from worsening when added to the company’s approved treatment, Opdivo, the company said Wednesday.
The result is a step forward for immunotherapy, a field that has seen only halting progress since the development of medicines like Opdivo and Merck’s rival treatment, Keytruda.
About the Author Reprints
